Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Mimedx (MDXG) Other financing activities (2011 - 2024)

Mimedx recorded quarterly Other financing activities of -$1.2 million in Q4 2024, down 205.18% quarter-over-quarter from $1.1 million in Q1 2024.

Mimedx's Other financing activities history runs 6 years deep, the most recent figure standing at -$1.2 million for Q4 2024.

In Q4 2024, Other financing activities changed N/A year-over-year to -$1.2 million; the TTM figure through Sep 2025 stood at -$1.2 million (down 205.18% YoY), while the FY2024 annual figure was -$57000.0, changed N/A from the prior year.
Other financing activities came in at -$1.2 million for Q4 2024 at Mimedx, down from $1.1 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $6.5 million in Q3 2020 to a low of -$3.3 million in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn
7	Evaxion A	62.56 Bn	62.54 Bn	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn
10	Mimedx	530.69 Mn	370.92 Mn	41.62 Mn

Historic Data

Download Data 🔒

Date	Value
Dec 31, 2024	-1.16 Mn
Dec 31, 2024	-1.16 Mn
Mar 31, 2024	1.10 Mn
Mar 31, 2024	1.10 Mn
Dec 31, 2020	-3.33 Mn
Dec 31, 2020	-3.33 Mn
Sep 30, 2020	6.54 Mn
Sep 30, 2020	6.54 Mn
Dec 31, 2019	-6.64 Mn
Dec 31, 2019	-6.64 Mn
Sep 30, 2019	595,000.00
Sep 30, 2019	595,000.00
Dec 31, 2016	-76,000.00
Dec 31, 2016	-76,000.00
Sep 30, 2016	45,000.00
Sep 30, 2016	45,000.00
Jun 30, 2016	41,000.00
Jun 30, 2016	41,000.00
Mar 31, 2016	20,000.00
Mar 31, 2016	20,000.00
Dec 31, 2015	504,000.00
Dec 31, 2015	504,000.00
Dec 31, 2011	47,800.00
Dec 31, 2011	47,800.00